A Phase 2 Open-Label, Multicenter Study of SNS-595 Injection in Patients With Platinum-Resistant Ovarian Cancer
Other objectives of this study are to evaluate Progression-free survival and measure CA-125
response rate.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Objective Response rate
Prior to Cycles 3, 5, 7, etc...
No
Sunesis Medical Monitor, MD
Study Director
Sunesis Pharmaceuticals
United States: Food and Drug Administration
SPO-0010
NCT00408603
November 2006
October 2010
Name | Location |
---|---|
Stanford University | Stanford, California 94305 |
Dana-Farber Cancer Institute | Boston, Massachusetts 02115 |
Massachusetts General Hospital | Boston, Massachusetts 02114-2617 |
Gynecologic Oncology Associates | Newport Beach, California 92663 |
Sharp Clinical Oncology Research | San Diego, California 92123 |
Premiere Oncology of Arizona | Scottsdale, Arizona 85260 |
Medstar Research Institute at Washington Hospital Center | Washington, District of Columbia 10010 |
Oncology Specialists, S.C. at Luthern General Advanced Care Center | Park Ridge, Illinois 60068 |
Louisville Oncology Clinical Research Program | Louisville, Kentucky 40202 |
The Harry and Jeanette Weinberg Institute at Franklin Square | Baltimore, Maryland 21237 |
Memorial Sloan Kettering Cancer Center (MSKCC) | New York, New York 10021 |
Kaiser Permanente NW Region | Portland, Oregon 97227 |
University of Pittsburgh Medical Center at Magee-Womens Hospital | Pittsburgh, Pennsylvania 15213 |
Hall and Martin, MD's, P.C. | Knoxville, Tennessee 37920 |